Santen has acquired Eyevance through a share purchase agreement, according to a press release.
The $225 million all-cash transaction makes Eyevance a wholly owned subsidiary of Santen.
Current Eyevance offerings include anti-inflammatory, anti-allergic, antifungal, anti-infective/anti-inflammatory fixed combination and tear lubricant products. Two products under development, Visovanq, a sterile vancomycin ophthalmic ointment, and Nexagon, a gel for persistent corneal epithelial defects, were excluded from the deal.
“Through this purchase, we will quickly establish a business base in the
Uncategorized